Biotechnology company developing first-in-class oral small molecules that overstress pathological cells to treat gastro-intestinal cancers. Its lead clinical drug candidate, BPR001-615, selectively targets BiP (GRP78), a key protein involved in cancer cell survival. The company is also developing additional programs in oncology, auto-immune and metabolic diseases.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €1 M | Dec, 2025 | unspecified |
Industries
Frequently Asked Questions
Where is BiPER Therapeutics located?
BiPER Therapeutics is located in Strasbourg, France.
What industries does BiPER Therapeutics operate in?
BiPER Therapeutics operates in the following industries: biotechnology, oncology, drug discovery.
When was BiPER Therapeutics founded?
BiPER Therapeutics was founded on 2026-05-21.
How much total funding has BiPER Therapeutics raised?
BiPER Therapeutics has raised a total of $1,000,000.
Who are the investors in BiPER Therapeutics?
The investors in BiPER Therapeutics are: MEDIN Fund Management Company, Bpifrance.
What is the primary focus of BiPER Therapeutics?
BiPER Therapeutics is a biotechnology company focused on developing first-in-class small molecule drugs that treat cancer by inducing unresolved endoplasmic reticulum stress, effectively forcing cancer cells to burn out.
What is the lead drug candidate being developed by BiPER Therapeutics?
The lead clinical drug candidate for BiPER Therapeutics is BPR001-615, which is a selective inhibitor of BiP designed for the treatment of gastrointestinal cancers through oral administration.
Where is BiPER Therapeutics based and when was it founded?
BiPER Therapeutics was founded in 2021 and is headquartered in Strasbourg, France.
How does BiPER Therapeutics use AI in its research and development?
BiPER Therapeutics integrates AI into its drug development process to connect wet lab data, predict pharmacokinetics and pharmacodynamics, optimize drug behavior, and assist in identifying the best patient populations for precision medicine.